Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19982712 | 0.81 | EPHX1 (0.33) | EPHX1SMN1; SMN2NPC1EPHX2NAAA | |
| SCHEMBL22132035 | 0.78 | EPHX1 (0.44) | EPHX1SMN1; SMN2NPC1EPHX2NAAA | |
| SCHEMBL14407371 | 0.73 | EPHX1 (0.40) | EPHX1SMN1; SMN2NPC1EPHX2NAAA | |
| SCHEMBL22131907 | 0.73 | MAPK1 (0.40) | EPHX1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29470599 | 0.72 | HPGD (0.51) | SMN1; SMN2KMT2AMEN1APEX1KDM4E | |
| SCHEMBL19974764 | 0.71 | EPHX1 (0.52) | EPHX1NPC1EPHX2KMT2ARAB9A | |
| SCHEMBL22187119 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AAPEX1ALDH1A1TGM2 | |
| SCHEMBL14642043 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AAPEX1ALDH1A1TGM2 | |
| SCHEMBL10803619 | 0.71 | ZDHHC20 (0.46) | EPHX1SMN1; SMN2NPC1EPHX2NAAA | |
| SCHEMBL19974730 | 0.71 | EPHX1 (0.38) | EPHX1SMN1; SMN2NPC1EPHX2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | EPHX1 372/4885SMN1; SMN2 706/4885NPC1 753/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | EPHX1 449/4885SMN1; SMN2 1086/4885NPC1 1213/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | EPHX1 372/4885SMN1; SMN2 706/4885NPC1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.